Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study
Patient satisfaction with anti-CGRP mAb therapy was high in this real-world study and correlated with effectiveness measured by the HIT-6 and significantly improved quality of life. Anti-CGRP mAbs are effective and safe for resistant migraine; they have a quick onset of action and provide lasting relief.
Authors
- A Sosa-Pons
- Núria Almendros-Abad (ORCID: https://orcid.org/0009-0001-9611-8796)
- Carlos Seguí Solanes (ORCID: https://orcid.org/0000-0002-5291-9831)
- Nuria Rudi Solá (ORCID: https://orcid.org/0000-0003-1288-8046)
- Laura Cardona-Roca (ORCID: https://orcid.org/0000-0003-3091-7322)
- Manuel Cano-Alonso (ORCID: https://orcid.org/0009-0006-5184-7481)
Institutions
- Hospital General de Granollers (ES)
Publication Details
- Journal
- BMC Neurology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12883-025-04384-1
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47